Skip to main content

Table 1 Key trials in ovarian cancer immunotherapy

From: Immunotherapeutic approaches to ovarian cancer treatment

Study Patients Treatment # of Patients Response Survival
Vald, Edwards Cancer Immunol Immunother 2010 Recurrent, platinum resistant ovarian cancer Interleukin-2 i.p. 24 CR: 4 Median Survival:
6 × 105 IU/ml weekly × 16 PR: 2 Non-Responder:
SD: 7 1.5 years
Responders: not reached
(24 -120+ months)
Hodi, Dranoff Recurrent metastatic ovarian cancer CTLA-4 Blockade: 9 CR: 0 Duration of Response:
PNAS 2008 Ipilupimab i.v. 3 mg/kg q 2 – 3 months   PR: 1 SD: 2,4,6+ Months
SD: 3 PR: 35+ Months
Diefenbach, Dupont “High Risk” ovarian cancer after surgery and 1st line chemo NY-ESO-1b peptide (position 157–165; 100 μg) + 0.5 mL Montanide ISA-51 s.c. q 3 weeks × 5 9 NA Median PFS: 13 months
Clin Cancer Res 2008 6/9 patients recurred
3 patient disease free after 25, 38, and 52
Fujita,Tanaka Clin Cancer Research 1995 NED after surgery and 1st line chemo 1.0 – 4.4 × 109 TIL after 1st line chemo 13 TIL NA 3-year DFS:
11 Control TIL: 82.1%
Control: 54.5%
3-year DFS, residual disease after surgery
TIL: 76.2%
Control: 33.3%
Chu, June Consolidation after 1st line treatment or secondary debulking Her-2/neu, hTERT, PADRE-loaded Dendritic cells +/− Cyclophosphamide 11 NA 5 recurrences
Cancer Immunol Immunother 2012 6 patients NED at 36 months
3-year OS 90%
Odunsi, Jaeger Consolidation after 1st line treatment I.d. rV-NY-ESO-1, 22 NA PFS: 21 months
PNAS 2012 3.1 × 107 PFU, monthly s.c. OS: 48 months
rF-NY-ESO-1, 7.41 × 107 PFU for 6 mo.
Rahma, Khleif HLA-A2.1 + stage III, IV, or recurrent ovarian Arm A: s.c. wt p53:264–272 peptide with Montanide and GM-CSF. 21 NA Arm A:
Cancer Immunol Immunother 2012 Immune responses 9/13 patients (69%), PFS: 4.2 months
Cancer over-expressing the p53 protein, no evidence of disease Arm B: i.v. wt p53:264–272 peptide-pulsed dendritic cells IV OS: 40.8 months
IL-2 in both cohorts Arm B:
Immune responses 5/6 patients (83%)
PFS: 8.7 months
OS: 29.6 months
  1. Adapted from: Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol. 2011 Mar 1;29(7):925–33.